Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label, Non Randomized Phase 2 Study With Safety Run-In Evaluating Efficacy and Safety of PQR309 in Patients With Relapsed or Refractory Lymphoma

NCT02249429 is registered in ClinicalTrials.gov with PIQUR Therapeutics AG as lead sponsor.

NCT NCT02249429
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02249429 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label, Non Randomized Phase 2 Study With Safety Run-In Evaluating Efficacy and Safety of PQR309 in Patients With Relapsed or Refractory Lymphoma
Lead sponsor
PIQUR Therapeutics AG
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2015
Completion date
September 11, 2018
Enrollment
53 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, malignant